These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33479048)

  • 1. CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma.
    Raj D; Nikolaidi M; Garces I; Lorizio D; Castro NM; Caiafa SG; Moore K; Brown NF; Kocher HM; Duan X; Nelson BH; Lemoine NR; Marshall JF
    Clin Cancer Res; 2021 Mar; 27(5):1538-1552. PubMed ID: 33479048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
    Raj D; Yang MH; Rodgers D; Hampton EN; Begum J; Mustafa A; Lorizio D; Garces I; Propper D; Kench JG; Kocher HM; Young TS; Aicher A; Heeschen C
    Gut; 2019 Jun; 68(6):1052-1064. PubMed ID: 30121627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
    Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
    Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
    Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEACAM7 expression contributes to early events of pancreatic cancer.
    Dhasmana A; Dhasmana S; Kotnala S; Laskar P; Khan S; Haque S; Jaggi M; Yallapu MM; Chauhan SC
    J Adv Res; 2024 Jan; 55():61-72. PubMed ID: 36828119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.
    Amit U; Uslu U; Verginadis II; Kim MM; Motlagh SAO; Diffenderfer ES; Assenmacher CA; Bicher S; Atoche SJ; Ben-Josef E; Young RM; June CH; Koumenis C
    Proc Natl Acad Sci U S A; 2024 Jul; 121(31):e2403002121. PubMed ID: 39047033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
    Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
    Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer.
    Ruixin S; Yifan L; Yansha S; Min Z; Yiwei D; Xiaoli H; Bizhi S; Hua J; Zonghai L
    Br J Pharmacol; 2024 Nov; 181(22):4628-4646. PubMed ID: 39129178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.
    Montemagno C; Cassim S; Pouyssegur J; Broisat A; Pagès G
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
    Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes.
    Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O
    Front Immunol; 2020; 11():1704. PubMed ID: 32849600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.
    Murad JP; Tilakawardane D; Park AK; Lopez LS; Young CA; Gibson J; Yamaguchi Y; Lee HJ; Kennewick KT; Gittins BJ; Chang WC; Tran CP; Martinez C; Wu AM; Reiter RE; Dorff TB; Forman SJ; Priceman SJ
    Mol Ther; 2021 Jul; 29(7):2335-2349. PubMed ID: 33647456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered T cells for pancreatic cancer treatment.
    Katari UL; Keirnan JM; Worth AC; Hodges SE; Leen AM; Fisher WE; Vera JF
    HPB (Oxford); 2011 Sep; 13(9):643-50. PubMed ID: 21843265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
    Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
    J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability.
    Hu JF; Wang ZW; Liao CY; Chen ZW; Kang FP; Lin CF; Lin TS; Huang L; Tian YF; Chen S
    Front Immunol; 2022; 13():958960. PubMed ID: 35990619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors.
    Rosewell Shaw A; Porter CE; Yip T; Mah WC; McKenna MK; Dysthe M; Jung Y; Parihar R; Brenner MK; Suzuki M
    Commun Biol; 2021 Mar; 4(1):368. PubMed ID: 33742099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas.
    Schölzel S; Zimmermann W; Schwarzkopf G; Grunert F; Rogaczewski B; Thompson J
    Am J Pathol; 2000 Feb; 156(2):595-605. PubMed ID: 10666389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma.
    Yazdanifar M; Zhou R; Grover P; Williams C; Bose M; Moore LJ; Wu ST; Maher J; Dreau D; Mukherjee AP
    Cells; 2019 Sep; 8(9):. PubMed ID: 31514488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
    Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
    J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.